Zhu AX, Kang Y-K, Yen C-J, et al. REACH-2: A randomized, double-blind, placebo-controlled phase III study of ramucirumab (Cyramza) versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 36, 2018 (suppl; abstr 4003).
NWO-subsidie voor onderzoek naar radioembolisatie van levertumoren
jul 2020 | Hepatologie, Maag-darm-leveroncologie, Radiotherapie